Press release
Proton Pump Inhibitors Market Set to Surpass US$ 5.6 Bn by 2034, Driven by Rising Prevalence of GERD and Acid-Related Disorders - TMR Analysis
Proton Pump Inhibitors (PPIs) Market Size Outlook 2034
The global Proton Pump Inhibitors (PPIs) market was valued at US$ 3.7 billion in 2023. The market is projected to grow at a CAGR of 4.0% from 2024 to 2034, reaching over US$ 5.6 billion by 2034. The steady expansion is supported by rising cases of gastroesophageal reflux disease (GERD), gastric ulcers, peptic ulcer disease (PUD), Zollinger-Ellison syndrome, and an aging population increasingly prone to gastrointestinal disorders.
👉 Get your sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19169
Market Overview
Proton pump inhibitors are among the most widely used drugs for reducing gastric acid production. Common PPIs include omeprazole, pantoprazole, esomeprazole, lansoprazole, rabeprazole, and dexlansoprazole. They remain the primary treatment option for GERD, erosive esophagitis, ulcer healing, and prevention of NSAID-induced gastritis.
The market continues to benefit from:
• Growing adoption of over-the-counter (OTC) PPIs
• Increasing diagnosis of acid reflux and lifestyle-related gastrointestinal disorders
• Shifts toward long-term maintenance therapy in chronic GERD patients
• Growing elderly population and rise in medication dependency
• Expansion of generic PPI formulations, driving accessibility and affordability
However, increasing awareness of potential long-term risks-such as kidney issues, micronutrient deficiencies, and infections-has driven healthcare providers toward optimized prescribing and step-down therapy, shaping future market dynamics.
Key Market Growth Drivers
1. Rising Incidence of GERD and Acid-Related Disorders
GERD prevalence is rising due to lifestyle changes, obesity, smoking, alcohol consumption, and dietary habits. With nearly 15-20% of the global population affected, demand for PPIs remains strong.
2. Growing Availability of OTC PPIs
Many PPIs have transitioned from prescription-only to OTC drugs, expanding consumer access and boosting market growth.
3. Aging Population
Older adults are more prone to gastrointestinal issues and chronic diseases requiring NSAIDs, increasing the demand for PPIs to prevent related gastric complications.
4. Increasing Use of NSAIDs and Antibiotics
The widespread use of NSAIDs-especially among arthritis and chronic pain patients-increases the need for PPIs to prevent stomach lining damage, driving consistent demand.
5. Expansion of Generic Manufacturing
Patent expiries of major branded PPIs have opened opportunities for cost-effective generics, promoting higher global adoption.
Analysis of Key Players in the Proton Pump Inhibitors (PPIs) Market
The global proton pump inhibitors (PPIs) market is fragmented, with numerous established and emerging pharmaceutical companies contributing to a competitive landscape. Market participants are increasingly pursuing strategic partnerships, product launches, regulatory approvals, and geographic expansion to strengthen their market position.
Leading manufacturers in the PPIs market include
• Pfizer
• Teva Pharmaceutical Industries Ltd
• LUPIN Limited
• Amneal Pharmaceuticals LLC
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Alembic Pharmaceuticals Limited
• Sanofi S.A.
• AstraZeneca
• Others Prominent Players.
These companies maintain strong product portfolios featuring widely used PPIs such as esomeprazole, omeprazole, pantoprazole, lansoprazole, and rabeprazole.
Key players have been analyzed in the proton pump inhibitors market report based on parameters including company overview, business segments, product portfolio, financial highlights, strategic initiatives, and recent developments.
👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19169
Key Developments
• November 2023 - Phathom Pharmaceuticals (U.S.)
The U.S. FDA approved vonoprazan (Voquenza) 10 mg and 20 mg tablets, a potassium-competitive acid blocker (PCAB) indicated for adults with all grades of erosive esophagitis. This approval introduces an innovative therapy after nearly three decades, marking a major advancement in GERD management.
• July 2023 - RaQualia Pharma & HK inno.N Corporation
RaQualia Pharma announced that PT Kalbe Pharma began sales of Tegoprazan in Indonesia. Tegoprazan, originally licensed by Korea-based HK inno.N, is now available in six countries-Korea, China, Mongolia, the Philippines, Mexico, and Indonesia-with regulatory and launch preparations underway in 30 additional markets. This signals accelerated international commercial expansion.
• June 2023 - Zydus Lifesciences Limited (India)
Zydus received USFDA approval for Esomeprazole Magnesium delayed-release oral suspension (20 mg and 40 mg). The drug is used to treat reflux-related disorders of the stomach and esophagus, reinforcing Zydus's footprint in the U.S. generics market.
Market Challenges & Opportunities
Challenges
1. Side Effects and Safety Concerns
Long-term PPI use is associated with kidney disease, fractures, infections, and nutrient deficiencies, affecting physician prescribing patterns.
2. Competition from H2 Receptor Antagonists (H2RAs)
Drugs like ranitidine substitutes and famotidine offer alternatives for mild acid reflux.
3. Growing Preference for Non-Pharmacological Therapies
Lifestyle modifications and surgical treatments are becoming more common in chronic GERD cases.
4. Patent Expirations
Branded drugs face pricing pressure due to generic competition.
Opportunities
1. Emerging Markets Growth
Improving healthcare infrastructure and insurance coverage in Asia and Africa open significant demand avenues.
2. Innovative Drug Delivery Technologies
Dual-release formulations and once-daily dosing regimens enhance patient compliance.
3. Combination Therapies for H. pylori
PPIs are integral to eradication therapy, creating stable demand.
4. E-commerce and Telemedicine Expansion
Online pharmacies and home delivery services are boosting OTC PPI sales worldwide.
Investment Landscape and ROI Outlook
The PPI market, though mature, continues to offer steady, moderate-return investment opportunities due to stable global demand and expansion in OTC drug consumption.
Investment Advantages
• High disease prevalence ensures predictable long-term demand.
• Strong generic sales potential in developing countries.
• Low manufacturing costs and high-volume production models ensure operational efficiency.
ROI Outlook
With a CAGR of 4.0%, the market offers low to medium risk and consistent returns, particularly for:
• Generic manufacturers
• Distribution networks
• OTC and consumer healthcare companies
• Regional pharmaceutical players expanding into gastroenterology
Market Segmentations
By Drug Type
• Omeprazole
• Esomeprazole
• Pantoprazole
• Lansoprazole
• Rabeprazole
• Dexlansoprazole
• Others
By Application
• GERD
• Peptic Ulcer Disease
• Zollinger-Ellison Syndrome
• Dyspepsia
• H. pylori Infection
• NSAID-Induced Ulcers
By Distribution Channel
• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• OTC Channels
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Why Buy This Report?
✔ Comprehensive analysis of PPI market trends through 2034
✔ In-depth review of growth drivers, restraints, and opportunities
✔ Competitive profiling of top pharmaceutical companies
✔ Detailed segmentation enabling targeted strategy development
✔ Insights for investors, pharma manufacturers, healthcare providers, and distributors
✔ Accurate market forecasting for strategic decision-making
👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=19169<ype=S
FAQs
1. What is the projected size of the PPIs market by 2034?
More than US$ 5.6 billion.
2. What is the market growth rate from 2024-2034?
A steady 4.0% CAGR.
3. Which drug type dominates the market?
Omeprazole, esomeprazole, and pantoprazole are widely used due to high efficacy.
4. What factors are driving market growth?
Rising GERD prevalence, aging population, and increasing OTC availability.
5. Which regions lead the market?
North America and Europe, while Asia-Pacific shows the fastest growth.
More Trending Research Reports-
• Gastric Cancer Diagnostics Market - https://www.transparencymarketresearch.com/gastric-cancer-diagnostics-market.html
• Cardiac Prosthetic Devices Market - https://www.transparencymarketresearch.com/cardiac-prosthetic-market.html
About Us Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact Us
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Proton Pump Inhibitors Market Set to Surpass US$ 5.6 Bn by 2034, Driven by Rising Prevalence of GERD and Acid-Related Disorders - TMR Analysis here
News-ID: 4303156 • Views: …
More Releases from Transparency Market Research Pvt Ltd
Global Aviation Battery Market Poised for Rapid Expansion, Surpassing US$ 10.6 B …
Aviation Battery Market Size Outlook 2035
The global aviation battery market was valued at US$ 3.4 billion in 2024. It is projected to reach US$ 10.6 billion by 2035, expanding at a CAGR of 11.0% from 2025 to 2035. This rapid growth is driven by the increasing adoption of electric and hybrid aircraft, advancements in lithium-based and solid-state battery technologies, and rising demand for energy-efficient, lightweight, and high-capacity power sources in…
Global Biodegradable Chelating Agents Market to Grow from US$ 1.80 Bn in 2024 to …
Biodegradable Chelating Agents Market Size Outlook 2035
The global biodegradable chelating agents market was valued at US$ 1.80 billion in 2024. It is projected to reach US$ 3.41 billion by 2035, expanding at a CAGR of 6.5% from 2025 to 2035. The market growth is primarily driven by the increasing demand for eco-friendly chemicals in water treatment, detergents, agriculture, and industrial applications, coupled with global regulations favoring sustainable alternatives to traditional…
CSTR Market to Reach US$ 3.3 Bn by 2035, Driven by Growing Adoption in Chemical, …
Continuous Stirred Tank Reactor (CSTR) Market Size Outlook 2035
The global Continuous Stirred Tank Reactor (CSTR) market was valued at US$ 2.1 billion in 2024. It is projected to reach US$ 3.3 billion by 2035, growing at a CAGR of 4.2% from 2025 to 2035. The steady growth is driven by increasing demand for efficient chemical and biochemical processes, expanding pharmaceutical production, and the adoption of automated and continuous reaction systems…
Global Piperazine Market to Expand from US$ 3.3 Bn in 2024 to US$ 5.5 Bn by 2035 …
Piperazine Market Size Outlook 2035
The global piperazine market was valued at US$ 3.3 billion in 2024 and is anticipated to reach US$ 5.5 billion by 2035, expanding at a CAGR of 4.7% from 2025 to 2035. The market is witnessing strong demand from pharmaceuticals, wastewater treatment, chemical manufacturing, and polymer applications. Rising regulatory pressure to adopt highly efficient chemical intermediates and growing investments in specialty chemicals are further accelerating market…
More Releases for PPI
PPI Market Analysis Current Landscape and Future Outlook
​The global PPI market was valued at approximately USD 4.9 billion in 2023 and is projected to reach around USD 7.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2032 .
PPI Market Overview
The PPI market is experiencing steady growth, driven by the increasing prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The aging global population…
PPI Market 2024 Trends, Analysis, Growth, Opportunities, Forecast to 2031
The global proton pump inhibitors market is estimated to grow at a significant CAGR during the forecast period. Many researchers have found that proton pump inhibitors have raised the risk of COVID-19 in patients taking these medications. The researchers of the American Journal of Gastroenterology, in 2020, conducted research in which more than 55,000 people taking proton pump inhibitors participated, out of which 3,476 said that they had tested positive…
FSA Gives Banks Extension to Deal with 2011 PPI Claims
The Financial Services Authority (FSA) has given high street banks more time to deal with payment protection insurance (PPI) mis-selling claims.
The FSA has given banks
Under FSA rules PPI complaints have to be responded to within eight weeks.
The extension gives firms time to deal with claims which had been put on hold. It has also given more time for the firms to deal with PPI complaints received since the…
PPI Claims Delayed By Banks But This Time The FSA Stand Firm
Many customers will remember with some sorrow the manner in which the bank charges fiasco turned into an ultimately unfortunate defeat for many consumers. The banks halted the stem of complaints by lodging a test case against the Office of Fair Trading and the FSA at the time issued a waiver to allow all bank charges complaints to be kept on hold.
In 2010 following countless assessments and investigations, the FSA…
Mis-sold PPI - The Worst Personal Finance Scandal Ever?
New information released by the Financial Services Authority (FSA) could see mis-sold PPI become the worst ever personal finance scandal to hit Britain.
The FSA believes it will receive 2.75 million complaints about mis-sold PPI over the next five years. Compensation to the customers who have been mis-sold PPI policies is expected to top £4 billion.
Could mis-sold PPI become Britain's worst ever personal finance scandal? If the level of complaints…
PPI Most Complained About Financial Problem
FOR IMMEDIATE RELEASE
London, UK, 16th September, 2010: Payment Protection Insurance (PPI) was the most complained about financial issue in the first half of 2010, according to new figures.
The Financial Ombudsman Service (FOS) has received 30,000 complaints from consumers who have been mis-sold the policies.
The body received three times more complaints about PPI than the combined totals for mortgages, investments, and pensions.
Overall, 84,212 new complaints were made to the FOS about…
